Statera Biopharma, Inc. (NASDAQ:STAB – Get Rating) was the target of a large increase in short interest in the month of October. As of October 15th, there was short interest totalling 2,390,000 shares, an increase of 444.2% from the September 30th total of 439,200 shares. Currently, 5.8% of the shares of the stock are sold short. Based on an average daily volume of 2,740,000 shares, the days-to-cover ratio is currently 0.9 days.

Statera Biopharma Stock Performance

STAB remained flat at $0.15 during midday trading on Friday. 516,431 shares of the company's stock were exchanged, compared to its average volume of 3,652,617. Statera Biopharma has a one year low of $0.11 and a one year high of $4.18. The company's fifty day moving average price is $0.17 and its 200-day moving average price is $0.22.

Institutional Trading of Statera Biopharma

Large investors have recently modified their holdings of the business. Raymond James Financial Services Advisors Inc. grew its position in shares of Statera Biopharma by 275.9% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 112,250 shares of the company's stock valued at $35,000 after purchasing an additional 82,391 shares during the last quarter. UBS Group AG acquired a new stake in shares of Statera Biopharma in the first quarter valued at approximately $37,000. Virtu Financial LLC grew its position in shares of Statera Biopharma by 409.2% in the first quarter. Virtu Financial LLC now owns 157,678 shares of the company's stock valued at $50,000 after purchasing an additional 126,715 shares during the last quarter. Northern Trust Corp grew its position in shares of Statera Biopharma by 335.9% in the first quarter. Northern Trust Corp now owns 171,110 shares of the company's stock valued at $54,000 after purchasing an additional 131,855 shares during the last quarter. Finally, Empery Asset Management LP purchased a new position in shares of Statera Biopharma during the first quarter valued at approximately $105,000. 8.40% of the stock is currently owned by institutional investors and hedge funds.

Statera Biopharma Company Profile

Statera BioPharma, Inc, a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers.

Featured Stories

• Get a free copy of the StockNews.com research report on Statera Biopharma (STAB)
• McDonald's Stock Sizzles, but Will it Hit a New All-Time High?
• Chevron Gushes More Profits; Is it Time for Investors to Buy?
• Can Comcast Monetize Existing Users for Streaming Success?
• Why is Amazon Stock Falling? Is the Sell-Off Overdone?
• Apple Inc. Stock Q4 Results Beat Negative Outlook, Stock Rises

Receive News & Ratings for Statera Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Statera Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.